ArticleMultiple sclerosis journal - experimental, translational and clinical
Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid-refractory multiple sclerosis relapses.European journal of neurology · 2024Trial
- Association between pregnancy timing and disability outcomes in women with mild relapse-onset multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Exit strategy patterns in second-line therapies for relapsing forms of multiple sclerosis.Acta neurologica Belgica · 2026Article
- Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomography.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosis.Neurological research and practice · 2025Review
- Multiple sclerosis lesions that impair memory map to a connected memory circuit.Journal of neurology · 2023Article
- Neurodegeneration in multiple sclerosis.WIREs mechanisms of disease · 2023Review
- Retinal Layer Thinning After Optic Neuritis Is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis.Neurology · 2022Observational
- How patients with multiple sclerosis acquire disability.Brain : a journal of neurology · 2022Article
- Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD.Frontiers in neurology · 2022Review
- Optical Coherence Tomography in the Differential Diagnosis of Patients with Multiple Sclerosis and Patients with MRI Nonspecific White Matter Lesions.Sensors (Basel, Switzerland) · 2021Article
- Plasma Exchange vs. Immunoadsorption: Effects on Immunological Markers and Predictive Value in Steroid-Refractory MS Attacks.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor.
objectiveTo identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-year disability and MRI outcomes.
methodsRelapse recovery was retrospectively assessed in 360 patients with MS using the return of the Expanded Disability Status Scale (EDSS), Functional System Scale and neurologic signs to baseline at least 6 months after onset. Univariate and multivariable models were used to associate recovery with demographic and clinical factors and predict 10-year outcomes.
resultsRecovery from relapses in the first 3 years was better in patients who were younger, on disease-modifying treatment, with a longer disease duration and without bowel or bladder symptoms. For every incomplete recovery, 10-year EDSS increased by 0.6 and 10-year timed 25-foot walk increased by 0.5 s. These outcomes were also higher with older age and higher baseline BMI. Ten-year MRI brain atrophy was associated only with older age, and MRI lesion volume was only associated with smoking.
conclusionsEarly initiation of disease-modifying treatment in MS was associated with improved relapse recovery, which in turn prevented long-term disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.